251 286 - Biotech Bayern

Contact:
Marcus Irsfeld
Fraunhoferstr. 9
D-82152 Martinsried
Phone: +49 (0) 89 8565-2840
Fax: +49 (0) 89 8565-2849
E-Mail: munich@trigen.de
Internet: www.trigen.de
Contact:
Brigitte Stempfer
Frankfurter Ring 193a
D-80807 München
Phone: +49 (0) 89 324 266-0
Fax: +49 (0) 89 324 266-199
E-Mail: mail@trionpharma.de
Internet: www.trionpharma.com
Contact:
Brigitte Stempfer
Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 700766 0
Fax: +49 (0) 89 700766 11
E-Mail: mail@trionresearch.de
Internet: www.trionresearch.com
108
Trigen Holdings AG
BIOTECH THERAPEUTICS & DIAGNOSTICS
Keywords: Drug Development, Small Molecules, Peptide/Protein,
Cardiovascular Diseases
Trigen Holdings AG is a biopharmaceutical company, with operations in Munich
and London and a leader in cardiovascular drug discovery and development,
focusing on thrombosis and vascular dysfunction. The company was formed in
2005 through the merger of Trigen Holdings plc (London,UK) and ProCorde
GmbH (Munich, Germany). Next to an extensive portfolio of exiting pre-clinical
and discovery stage programmes targeting thrombosis, atherosclerosis and
other cardiovascular pathologies, the company benifits from two established
discovery platforms, SIGSCREEN® and THROMSCAN® which have been applied in
collaborations with a number of multinational pharmaceutical companies.
TRION Pharma GmbH
BIOTECH THERAPEUTICS & DIAGNOSTICS
Keywords: Drug Development, Antibody, Immune Therapy
TRION Pharma develops a new class of trifunctional antibodies (triomab®)
for highly effective cancer treatments. A state-of-the-art production plant
allows cost-effective large-scale manufacture according to international
GMP standards. The efficacy of the triomab® antibodies in terms of tumour
elimination and induction of a polyclonal humoral and cellular anti-tumour
immunity has been proven in animal models and in in vivo applications.
Catumaxomab and ertumaxomab are currently being developed in a clinical
programme featuring several clinical trials together with our cooperation
partner Fresenius Biotech. Market entry for the first antibody is expected
in 2008.
TRION Research GmbH
BIOTECH DNA/PROTEIN ANALYTICS
Keywords: Drug Development, Antibody Production Service, Immune Therapy
TRION Research develops a new class of intact trifunctional antibodies
(triomab®) which are specifically targeted at characteristic antigens of tumours,
such as B-cell-lymphoma and malignant melanoma. The advantage of these
trifunctional antibodies over conventional therapeutic approaches is the fact
that they simultaneously activate two immunological cascades and are thus
particularly effective in destroying tumour cells. TRION Research is further
active in the development of pharmaceutical diagnostics, focussing on pharmacodynamic
and pharmacokinetic analyses in immunotherapeutic clinical studies.